



**STATEMENT OF AUTHORITY
AND
CONFIDENTIALITY COMMITMENT FROM
THE UNITED STATES FOOD AND DRUG ADMINISTRATION
NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED
BY THE
*AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA OF BRAZIL***

The *Agência Nacional de Vigilância Sanitária* of Brazil (ANVISA) is authorized to disclose non-public information to the United States Food and Drug Administration (FDA) regarding ANVISA-regulated products as part of cooperative law enforcement or cooperative regulatory activities. ANVISA proposes to share non-public information regarding, among other things, the safety, effectiveness, or quality of ANVISA-regulated products with the FDA.

This Commitment is intended to strengthen communication between ANVISA and FDA to enhance their ability to protect and promote the health and safety of their respective populations with respect to products within the regulatory jurisdiction of ANVISA and FDA.


FDA understands that some of the information it receives from ANVISA may include non-public information exempt from public disclosure under the laws and regulations of Brazil, such as confidential commercial information; trade secret information; personal privacy information; law enforcement information; or internal, pre-decisional information. FDA understands that this non-public information is shared in confidence and that ANVISA considers it critical that FDA maintain the confidentiality of the information. Public disclosure of this information by FDA could seriously jeopardize any further scientific and regulatory interactions between ANVISA and FDA. ANVISA will advise FDA of the non-public status of the information at the time that the information is shared.

Therefore, FDA certifies that it:

1. has the authority to protect from public disclosure such non-public information provided to FDA in confidence by ANVISA;
2. will not publicly disclose such ANVISA-provided non-public information without the written authorization of the owner of the information, the written authorization from the individual who is the subject of the personal privacy information, or a written statement from ANVISA that the information no longer has non-public status;

3. will inform ANVISA promptly of any effort made by judicial or legislative mandate to obtain ANVISA-provided non-public information from FDA. If such judicial or legislative mandate orders disclosure of ANVISA-provided non-public information, FDA will take all appropriate legal measures in an effort to ensure that the information will be disclosed in a manner that protects the information from public disclosure; and
4. will promptly inform ANVISA of any changes to U.S. laws, or to any relevant policies or procedures, that would affect FDA's ability to honor the commitments in this document.

For the FDA:



Margaret A. Hamburg, M.D.
Commissioner of Food and Drugs

September 24, 2010
Date

Address: 10903 New Hampshire Avenue
Building 1, Room 2217
Silver Spring, MD 20993

Telephone: 301-796-5000

Facsimile: 301-847-3531

**STATEMENT OF AUTHORITY
AND
CONFIDENTIALITY COMMITMENT FROM
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA OF BRAZIL
NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED
BY
THE UNITED STATES FOOD AND DRUG ADMINISTRATION**

The United States Food and Drug Administration (FDA) is authorized under 21 C.F.R. § 20.89 to disclose non-public information to the *Agência Nacional de Vigilância Sanitária* of Brazil (ANVISA) regarding FDA-regulated products as part of cooperative law enforcement or cooperative regulatory activities. The FDA proposes to share non-public information regarding, among other things, the safety, effectiveness, or quality of FDA-regulated products with ANVISA.

This Commitment is intended to strengthen communication between ANVISA and the FDA to enhance their ability to protect and promote the health and safety of their respective populations with respect to products within the regulatory jurisdiction of ANVISA and the FDA.

ANVISA understands that some of the information it receives from the FDA may include non-public information exempt from public disclosure under the laws and regulations of the United States of America, such as confidential commercial information; trade secret information; personal privacy information; law enforcement information; or internal, pre-decisional information. ANVISA understands that this non-public information is shared in confidence and that the FDA considers it critical that ANVISA maintain the confidentiality of the information. Public disclosure of this information by ANVISA could seriously jeopardize any further scientific and regulatory interactions between the FDA and ANVISA. The FDA will advise ANVISA of the non-public status of the information at the time that the information is shared.


Therefore, ANVISA certifies that it:

1. has the authority to protect from public disclosure such non-public information provided to ANVISA in confidence by the FDA;
2. will not publicly disclose such FDA-provided non-public information without the written authorization of the owner of the information, the written authorization from the individual who is the subject of the personal privacy information, or a written statement from FDA that the information no longer has non-public status;
3. will inform the FDA promptly of any effort made by judicial or legislative mandate to obtain FDA-provided non-public information from ANVISA. If such judicial or legislative mandate orders disclosure of FDA-provided non-public information, ANVISA will take all appropriate legal measures in an effort to

ensure that the information will be disclosed in a manner that protects the information from public disclosure; and

4. will promptly inform the FDA of any changes Brazil's laws, or to any relevant policies or procedures, that would affect ANVISA's ability to honor the commitments in this document.

For ANVISA:



Dirceu Raposo de Mello, Ph.D.
Director Chairman

24/09/2010
Date

Address: SIA, Trecho 5, Área Especial 57 Cobertura
Brasília – DF, Brasil
CEP: 71.205-050

Telephone: +55 61 3462-5406

Facsimile: +55 61 3462-5414